Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	7.5	-	-	9.43	18.44
Revenue Growth (YoY)	-	-	-	-48.83%	-42.68%
Cost of Revenue	300.94	210.39	167.51	105.77	75.46
Gross Profit	-293.44	-210.39	-167.51	-96.33	-57.03
Selling, General & Admin	79.63	68.9	46.54	32.81	21.97
Operating Expenses	79.63	68.9	46.54	32.81	21.97
Operating Income	-373.07	-279.3	-214.05	-129.14	-78.99
Interest & Investment Income	26.83	41.94	27.62	8.71	0.47
Currency Exchange Gain (Loss)	1.35	-1.06	0.2	-1.89	0.36
EBT Excluding Unusual Items	-344.89	-238.42	-186.24	-122.32	-78.17
Gain (Loss) on Sale of Investments	-	-	3.55	-2.93	-0.72
Pretax Income	-344.89	-238.42	-182.69	-125.26	-78.89
Income Tax Expense	1.02	-4.09	-0.29	0.12	-0.01
Net Income	-345.91	-234.33	-182.39	-125.37	-78.88
Preferred Dividends & Other Adjustments	-	-	-	-	-1.8
Net Income to Common	-345.91	-234.33	-182.39	-125.37	-77.09
Shares Outstanding (Basic)	79	78	67	61	44
Shares Outstanding (Diluted)	79	78	67	61	44
Shares Change (YoY)	1.75%	16.45%	10.48%	38.77%	21.09%
EPS (Basic)	-4.36	-3.01	-2.73	-2.07	-1.77
EPS (Diluted)	-4.36	-3.01	-2.73	-2.07	-1.77
Free Cash Flow	-279.92	-184.46	-156.73	-103.92	-71.55
Free Cash Flow Per Share	-3.53	-2.37	-2.34	-1.72	-1.64
Operating Margin	-4974.27%	-	-	-1368.91%	-428.45%
Profit Margin	-4612.13%	-	-	-1328.95%	-418.11%
Free Cash Flow Margin	-3732.23%	-	-	-1101.57%	-388.09%
EBITDA	-370.53	-276.74	-211.99	-127.74	-78.09
D&A For EBITDA	2.54	2.56	2.06	1.41	0.91
EBIT	-373.07	-279.3	-214.05	-129.14	-78.99

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q